Companies in the life science industry – consisting of MedTech, Pharmaceuticals and service providers in the healthcare sector – represent one of the main pillars of the Swiss economy. In recent years, they have even been the most important growth driver for Switzerland as a business location.
The ongoing digitalisation in the Healthcare sector offers new opportunities. The interaction between Healthcare service providers and patients can be simplified by technical tools. In the future, new diagnosis and care options are to be created in this way. On the one hand, patients can be monitored cost-effectively, while on the other hand the high availability of personalised data opens the possibility for more individualised treatments.
Informed consumers are driving real change in the healthcare ecosystem and we are seeing a new era of consumer-centric health systems emerge. Patients are becoming consumers of healthcare devices and services which is driving demand for more convenient, transparent, and personalised healthcare services. The established firms are adapting through innovation and acquisitions. However, the changing consumer behaviour has also provided opportunities for new entrants in the Life Science sector as e.g. consumer companies such as Nestlé.
Big Data and analytic capabilities will be essential for success in the pharma, healthcare and medtech industry as it enables more efficient diagnostics, helps to understand diseases, and supports to train artificial intelligence engines within healthcare institutions to increase physician efficiency. Recent collaborations between pharma and tech companies show that life science companies are actively seeking partners in the tech industry.
On 29 September 2020 Siegfried group reached an agreement with Novartis to acquire two pharmaceutical production facilities in Spain. This will considerably expand capacity and technological capabilities of Siegfried and thereby increases the potential for profitable growth of the group. At the same time, Siegfried has agreed a close cooperation with Novartis.
On 10 October 2020 Nestlé announced the successful takeover of Aimmune Therapeutics. Aimmune Therapeutics is specialised in the development and marketing of drugs to counteract life-threatening food allergies. Nestlé already held a stake in the company before the transaction.
Vifor Pharma sells OM Pharma, among others, to Etienne Jornod, the long-standing CEO of the Galenica group. OM Pharma is mainly active in the field of microbial-derived immune-therapeutics. The sale of the division is part of a portfolio streamlining and continued focus on the group’s core activities in the field of nephrology.
In late March 2021, the Swiss affiliate of the global pharmaceutical company Takeda successfully divested part of its home delivery business to a Swiss partner who will provide these services on behalf of Takeda in the future. The divestment also included an existing Pharmacy serving part of a German-speaking region of Switzerland.
IFBC acted as exclusive M&A advisor to Takeda during the entire transaction process. IFBC supported Takeda in preparing and structuring the transaction, conducted a meaningful buyer approach, coordinated the due diligence, and supported the contract negotiations.
Takeda is a global, R&D-driven biopharmaceutical leader headquartered in Japan. Takeda focuses on four therapeutic areas: oncology, rare genetic and hematology, neuroscience, and gastroenterology. Over 50’000 Takeda employees are committed to improving quality of life for patients and to working with partners in health care in more than 70 countries.
IFBC prepared a financial opinion for Colosseum Dental Group AG on the financial adequacy of the value of a subsidiary.
The Colosseum Dental Group is a leading pan-European dentistry group. The main owner of Colosseum Dental is Jacobs Holding AG.
IFBC was engaged by Sonova to assess the underlying cost of capital rates as well as the applied model for the valuation of the subsidiaries in the context of STAF in terms of best practice and to confirm the correct implementation. As part of the review, the planning assumptions made had to be checked for plausibility from an external perspective.
The Sonova Group is the world's leading provider of hearing instruments. The company is listed on the SIX Swiss Exchange.
IFBC developed a tool for Vifor Pharma with which the bonus can be calculated for the entire management based on the developed concept. In addition to an overall overview of the bonus calculations, the tool can be used to automatically generate an individual summary of the bonus calculation for each recipient as a basis for internal communication.
The Vifor Pharma Group is a global specialty-pharmaceutical company headquartered in Switzerland. The company’s goal is to become a global leader in iron deficiency, nephrology and cardiorenal therapies.
Die Vifor Pharma Gruppe ist ein globales Spezialitäten-Pharmaunternehmen mit Hauptsitz in der Schweiz. Sie hat sich zum Ziel gesetzt, globale Marktführerin in den Bereichen Eisenmangel, Nephrologie und kardiorenale Therapien zu werden.
The following graphs analyse the life science and healthcare industry over the past five years. The graphs show the development of the average semi-annual transaction multiples as well as a comparison between the trading multiples of listed companies in individual sub-sectors and per region as of the end of June 2020. The analysis is based on the Bloomberg database. In terms of size, a distinction is made between companies/transactions with a market capitalization of below (low-mid market) or above (large companies) USD 150 million.